Crotedumab Antibody

SKU: orb1980582

Description

Crotedumab (REGN1193) is a humanized anti-GCGR antibody utilized in diabetes research. It functions by antagonizing the glucagon receptor, leading to reduced fasting blood glucose and improved glucose tolerance in preclinical studies, supporting its investigation for metabolic disease therapeutics.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1452387-69-7
• MW: 146.82 kDa
• Purity: 96.61% (SEC-HPLC)
• Target: Glucagon Receptor

Bioactivity

• Target IC50:
  GCGR:0.1 nM (Kd)
• In Vivo:
  Administration of Crotedumab (a single subcutaneous injection) to diabetic OB/OB and diet-induced obese mice reduced blood sugar to levels observed in GCGR deficient mice. In diet-induced obese mice, Crotedumab reduced food intake, adipose tissue mass, and body weight. A single administration of Crotedumab in diabetic cynomophagus monkeys normalized fasting blood sugar and glucose tolerance, and increased circulating levels of glucagon and amino acids.
• In Vitro:
  Crotedumab inhibits glucagon-induced signaling in transfected human, monkey, mouse, and rat HEK293 cells via GCGR with IC50 values of 0.65, 3.2, 0.94, and 1.0 nM, respectively.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

REGN1193, REGN 1193, Anti-GCGR Reference Antibody

Quick Database Links

Gene Symbol

Glucagon Receptor